Anticoagulation Strategies for Primary Percutaneous Coronary Intervention

Anticoagulation in percutaneous coronary intervention

Balancing safety and efficacy of anticoagulation strategies is a fundamental goal in the performance of percutaneous coronary interventions. The ideal anticoagulant in the catheterization laboratory should effectively prevent thrombosis, yield a low bleeding risk, be titratable to individual clinical needs, be reversible when clinically indicated and be administered without the need for complic...

Anticoagulation strategies for primary percutaneous coronary intervention: current controversies and recommendations.

Primary percutaneous coronary intervention for all?

REPERFUSION THERAPY WITH THROMBOLYSIS OR PRImary percutaneous coronary intervention (PCI) has been a major advance in the treatment of acute ST-segment elevation myocardial infarction (MI), with a 25% reduction in mortality with thrombolysis. Primary PCI has been considered in the American College of Cardiology/American Heart Association (ACC/AHA) guidelines in 1999 to be an alternative to thro...

Early anticoagulation may improve preprocedural patency of the infarct-related artery in primary percutaneous coronary intervention.

ht ghest risk. Hence, our results would be valid for this population. e second limitation is the small sample size and limited number adverse events, which impedes precise adjustment for all the riables potentially related to mortality, and limits the robustness the results. Therefore, we conclude that in patients hospitalized for ACS, evated IPF values determined in the first 24 h following mi...

Effect of Melatonin on Cardiac Injury after Primary Percutaneous Coronary Intervention: a Randomized Controlled Trial

Several studies have reported that the antioxidant properties of melatonin can provide cardiac protection through scavenging of free radicals. This study sought to investigate the efficacy of melatonin on cardiac biomarkers, myocardial-specific protein high sensitive troponin-T (hs-TnT) and creatine kinase-MB (CK-MB), in patients with ST-segment elevation myocardial infarction (STEMI) undergoin...